Skip to main content
Premium Trial:

Request an Annual Quote

ABI Accelerates Next-Gen Sequencer Launch; Fiscal Q4 Sales Rise 7 Percent

NEW YORK (GenomeWeb News) — Applied Biosystems today said that it is accelerating by at least three months the formal launch of its SOLiD next-generation DNA sequencer.
The company also said that fiscal fourth-quarter revenues rose 7 percent as R&D spending surged 15.6 percent and profit grew 14.5 percent.  
Tony White, CEO of ABI parent Applera, said that “based on positive [early-access] customer feedback and progress in our manufacturing process” of the SOLiD system “we are accelerating plans to expand production and commence a full commercial release in October.”
The company had originally planned to launch the tool early next year.
Total receipts for the three months ended June 30 increased to $557 million from $523 million year over year.
Revenue from the company’s DNA-sequencing segment ticked up around 1 percent to $139 million; real-time PCR and applied genomics sales rose 13 percent to $193 million; mass spectrometry revenue increased 9 percent to $146 million; core PCR and DNA-synthesis sales slipped 7 percent to $48 million; while “other” sales grew 9 percent to $32 million.  
R&D spending rose to $53.5 million from $46.3 million in the year-ago period. That increase was due to investments made in developing the SOLiD instrument, the company said.  
ABI’s profit for the fourth quarter increased to $87.8 million from $76.7 million.
ABI said it expects “mid- to high-single-digit growth” overall for fiscal 2008, with increased revenue for both products and consumables.

The Scan

Test of the China Initiative

According to Science, the upcoming trial of Harvard University chemist Charles Lieber will test the US China Initiative.

Collaborative Approach

A virologist who spotted the Omicron variant of SARS-CoV-2 tells the Associated Press that its detection was aided by scientific sharing.

Genes of a Guide Dog

Wired reports on a study aimed at uncovering genes involved in being a successful guide dog.

PLOS Papers on RNAs in Metastatic Prostate Cancer, Ebola Field Lab, Embryonic RNA Editing

In PLOS this week: circRNA-mediated ceRNA network points to prostate cancer biomarkers, Ebola testing at frontline field laboratory, and more.